Public Health Programs Responsible For Dip In Uninsured Rate Says APHA, Urges Strengthening Medicaid And Medicare Statement from Georges C. Benjamin, MD, FACP, Executive Director. "While we welcome news today from the U.S. Census Bureau that the number of uninsured Americans has declined, the picture is not all rosy. Yes, the number of people without
health insurance has decreased from 47 million in 2006 to 45.7 million in 2007, but it's the government public
health programs that are picking up the slack.
Source: www.medicalnewstoday.comCutting Edge Technology For Arrhythmia Highlighted At Heart Rhythm Congress 2008 - Siemens Innovations Designed To Meet Clinical Needs Siemens
Healthcare offers a range of cardiac imaging solutions for minimally invasive routine procedures, advanced magnetic navigation electrophysiology and hybrid solutions for the operating theatre environment.
Source: www.medicalnewstoday.comInvacare Corporation Launches Website Dedicated To Team Invacare Paralympians Invacare Corporation (NYSE: IVC) and Invacare Top End, the company's sports and recreation division, are proud to launch an online feature dedicated to the Team Invacare athletes who are participating in the Paralympics in Beijing, China. It may be viewed at www.invacare.com/2008Paralympics.
Source: www.medicalnewstoday.comPeakdale Molecular Launches AssayReady4U(TM) In Collaboration With ChemPrintCo LLC AssayReady4U(TM) is an online based storefront which allows drug discovery researchers the ability to search, design and select compounds from a live physical collection of screening compounds. Then, using additional options, build their final assay by selecting the exact amount and concentration required to perform their own unique experiments.
Source: www.medicalnewstoday.comParkinson Disease Support Group Brings World Class Conference To Rome, Georgia The 3rd Annual Southeastern Parkinson Disease Conference will be held at Berry College in Rome, Georgia on November 6 - 8, 2008. Nationally and Internationally recognized experts in their fields will present programs on various aspects of living with Parkinson Disease. Early Registration is $75.
Source: www.medicalnewstoday.comLong-Term NHS Vacancy Rates Continue To Fall, UK Statistics published by The NHS Information Centre show that vacancy rates across the NHS are continuing to fall, with long-term vacancy rates for all of the main staff groups now below 1.0 per cent. The NHS Vacancy Survey 2008 reports on NHS vacancies that remained unfilled for three months or more on 31 March 2008.
Source: www.medicalnewstoday.comHospital Cost Increases Appear To Be Slowing, USA The cost of patient care in U.S. hospitals rose just under 1 percent between 2005 and 2006, much slower than the average 5.3 percent per year between 1997 and 2005, according to the latest News and Numbers from the Agency for
Healthcare Research and Quality.
Source: www.medicalnewstoday.comACUITY 1-Year Sub-Analysis Published In Journal Of The American College Of Cardiology Intervention Triage strategY study, published in the September 2, 2008 issue of the Journal of American College of Cardiology, shows that Angiomax® (bivalirudin) monotherapy provides moderate- and high-risk (unstable angina (UA)/non - ST elevation myocardial infarction) acute coronary syndrome (A
Source: www.medicalnewstoday.comAPHA Members Named Among The 100 Most Powerful People In Health Care Modern
Healthcare magazine has named Georges C. Benjamin, MD, FACP, FACEP (Emeritus), executive director of the American Public
Health Association (APHA), as one of the 100 most powerful people in
health care for 2008. Dr. Benjamin shares this honor with current APHA members Carolyn Clancy, MD; Karen Davis, PhD; and Margaret (Peggy) O'Kane.
Source: www.medicalnewstoday.comTreatment For Cachexia - Ark's Vitor™ Commences Patient Enrolment Into Phase III Pilot Study Ark Therapeutics Group plc ("Ark" or the "Company") announces that enrolment of patients into its Phase III pilot study for VitorTM (Study 208) has commenced. VitorTM is Ark's product to treat cachexia (involuntary muscle wasting) associated with cancer. Study 208 is a blinded, randomised, placebo controlled, multicentre trial in up to 64 patients being conducted in five countries in Europe.
Source: www.medicalnewstoday.com
# posted by Network @ 6:00 AM
